Scholarly communication in a digital world: the role of the digital repository at the Raman Research Institute

Information and communication technologies have changed the landscape of information handling activities. The proliferation of electronic resources and a paradigm shift from print to electronic format of journals, has led to another crisis due to the escalating costs of electronic resources, dwindling library budgets and cuts in journal subscriptions. Libraries have tried to overcome this situation by a dual approach, viz. consortia deals on one hand to access more information with optimal payment and open access scholarly publishing and communication on a worldwide basis on the other hand. In the last few years, the Open Access Movement has been gaining momentum and many journal publishers are also supporting this cause. With the availability of open source software for creating repositories, many institutes have established institutional repositories in support of open access. Realizing the importance and the benefits of such a repository at the institute level, RRI Library has set up the RRI Digital Repository. In this paper, we describe the growth and evolution of the repository, the problems encountered, the solutions explored, the strategies formulated to add relevant content and finally lessons learnt while executing the project

SYNTHESIS AND CRYSTAL STRUCTURE ANALYSIS OF 3 - (4 - METHOXYBENZYL) - 2, 3 – DIHYDRO - 4H – CHROMAN – 4 - ONE

3-(4-methoxybenzyl)-2,3-dihydro-4H-chroman-4-one(C17H16 O3) was synthesized by refluxing 2'-Hydroxydihydrochalcone dissolved in ethanol with paraformaldehyde and 50% aqueous diethylamine. The compound is characterized by IR,1HNMR, MS and X-ray diffraction studies. The X-ray structure analysis indicates that the crystal suffers from the positional disorder over two positions, atomC1 and C9 with required site occupancies of 0.590 and 0.410 leading to a conformational difference between the major and minor components. After applying similarity restraints, the final reliability index is 0.0275 for 2209 unique reflections .The crystal packing is stabilized by inter molecular C-H…O, C-H…π and π …π interactions

3-(4-Chloro­phen­yl)quinazolin-4(3H)-one

In the title compound, C14H9ClN2O, the quinazoline unit is essentially planar, with a mean deviation from the least-squares plane defined by the ten constituent ring atoms of 0.027 (2) Å. The dihedral angle between the mean plane of the quinazoline ring system and the 4-chloro­phenyl ring is 44.63 (5)°. In the crystal, mol­ecules are linked by inter­molecular C—H⋯N and C—H⋯O hydrogen bonds, forming infinite chains of alternating R22(6) dimers and R22(14) ring motifs

3-(4-Bromo­phen­yl)quinazolin-4(3H)-one

In the title compound, C14H9BrN2O, the quinazoline unit is essentially planar, with a mean deviation of 0.058 (2) Å from the least-squares plane defined by the ten constituent ring atoms. The dihedral angle between the mean plane of the quinazoline ring system and the 4-bromo­phenyl ring is 47.6 (1)°. In the crystal, mol­ecules are linked by inter­molecular C—H⋯N and C—H⋯O hydrogen bonds, forming infinite chains of alternating R 2 2(6) dimers and R 2 2(14) ring motifs

Post-intervention Status in Patients With Refractory Myasthenia Gravis Treated With Eculizumab During REGAIN and Its Open-Label Extension

OBJECTIVE: To evaluate whether eculizumab helps patients with anti-acetylcholine receptor-positive (AChR+) refractory generalized myasthenia gravis (gMG) achieve the Myasthenia Gravis Foundation of America (MGFA) post-intervention status of minimal manifestations (MM), we assessed patients' status throughout REGAIN (Safety and Efficacy of Eculizumab in AChR+ Refractory Generalized Myasthenia Gravis) and its open-label extension. METHODS: Patients who completed the REGAIN randomized controlled trial and continued into the open-label extension were included in this tertiary endpoint analysis. Patients were assessed for the MGFA post-intervention status of improved, unchanged, worse, MM, and pharmacologic remission at defined time points during REGAIN and through week 130 of the open-label study. RESULTS: A total of 117 patients completed REGAIN and continued into the open-label study (eculizumab/eculizumab: 56; placebo/eculizumab: 61). At week 26 of REGAIN, more eculizumab-treated patients than placebo-treated patients achieved a status of improved (60.7% vs 41.7%) or MM (25.0% vs 13.3%; common OR: 2.3; 95% CI: 1.1-4.5). After 130 weeks of eculizumab treatment, 88.0% of patients achieved improved status and 57.3% of patients achieved MM status. The safety profile of eculizumab was consistent with its known profile and no new safety signals were detected. CONCLUSION: Eculizumab led to rapid and sustained achievement of MM in patients with AChR+ refractory gMG. These findings support the use of eculizumab in this previously difficult-to-treat patient population. CLINICALTRIALSGOV IDENTIFIER: REGAIN, NCT01997229; REGAIN open-label extension, NCT02301624. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that, after 26 weeks of eculizumab treatment, 25.0% of adults with AChR+ refractory gMG achieved MM, compared with 13.3% who received placebo

Minimal Symptom Expression' in Patients With Acetylcholine Receptor Antibody-Positive Refractory Generalized Myasthenia Gravis Treated With Eculizumab

The efficacy and tolerability of eculizumab were assessed in REGAIN, a 26-week, phase 3, randomized, double-blind, placebo-controlled study in anti-acetylcholine receptor antibody-positive (AChR+) refractory generalized myasthenia gravis (gMG), and its open-label extension

India CSR report 2019: trends and prospects of CSR

This report studies the evolution & historical background of Corporate Social Responsibility (CSR) and offers a comprehensive overview of the current CSR practices in India, it offers policy suggestions to improve effectiveness and enlarging the scope of CSR

Microfinance India : the social performance report 2013/ Srinivasan, Girija

xviii,156 p. : ill, tab.; 30 cm

Microfinance India : the social performance report 2013/ Srinivasan, Girija

xviii,156 p. : ill, tab.; 30 cm

Rapid estimation of zinc and copper in tent cloth materials using flame AAS/ ICP- AES

35-37A rapid, simple, ecofriendly and cost effective method is described for the determination of Zn and Cu in tent cloth materials using flame Atomic Absorption Spectrometry (F-AAS) and or Inductively Coupled Plasma Atomic Emission Spectroscopy (ICP-AES) a tier the selective dissolution of Zinc and Copper naphthenates into ammoniacal ethylene diamine tetra acetic acid (EDTA) in solutions. EDTA in ammoniacal medium is used as chelating agent to leach the Zinc and Copper from their respective naphthenates. The solutions are filtered and made up to a known volume. An acidity of 5% v/v is maintained w.r.t HNO3 prior to their aspiration either in to flame AAS or ICP-AES for their individual estimation . This method has been app lied to some tent cloth samples and the Zn and Cu values are compared with the standard dry ashing/ignition method as per American Society for Testing Materials (ASTM) procedure. The values so obtained are in very good agreement with the standard ignition procedure both by F-AAS/ ICP-AES. The relative error by the proposed method varies from < 1% to 4.50 % RSD for both Zn and Cu depending upon the content of the elements